Drugs that contain Ivacaftor; Lumacaftor
1. Drug name - ORKAMBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(4 years from now) | |
| US10597384 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(6 years from now) | |
| US8507534 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(7 years from now) | |
| CN102652128A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Mar, 2015
(7 years ago) | |
| CN101006076B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN104788328A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN104788328B | VERTEX PHARMS INC | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN101935301B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN103641765A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101006076A | VERTEX PHARMS INC | Regulator Of Atp-Abc Transport Protein |
Jun, 2025
(2 years from now) | |
| CN107501099A | VERTEX PHARMS INC | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN101891680B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN107501099B | VERTEX PHARMS INC | Modulator Of Atp-Binding Cassette Transport Protein |
Jun, 2025
(2 years from now) | |
| CN103641765B | VERTEX PHARMS INC | Atp-Binding Cassette Transport Proteins Regulating Agent |
Jun, 2025
(2 years from now) | |
| CN101935301A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101891680A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101384172B | VERTEX PHARMS INC | N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form |
Dec, 2026
(4 years from now) | |
| CN101384172A | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| CN103626744B | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| CN101910156A | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| CN103626744A | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| CN101910156B | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| IN282654B | VERTEX PHARMS INC | Modulators Of Atpbinding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1773816B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP1773816A2 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP2502911A3 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787A1 | VERTEX PHARMS INC | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2489659B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2489659A1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787B1 | VERTEX PHARMS INC | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911A2 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1993360A4 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360A2 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360B1 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705A1 | VERTEX PHARMS INC | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705B1 | VERTEX PHARMS INC | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP2225230A1 | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| EP2225230B1 | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| EP3170818B1 | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| EP3170818A1 | VERTEX PHARMS INC | Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid |
Dec, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741933 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(4 years from now) | |
| US7973038 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(4 years from now) | |
| US9216969 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(4 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
| US8653103 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Dec, 2028
(6 years from now) | |
| US9150552 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(6 years from now) | |
| US10076513 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(6 years from now) | |
| US11052075 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(6 years from now) | |
| US8846718 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(6 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) | |
| US9192606 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2029
(7 years from now) | |
| US8716338 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(7 years from now) | |
| US8993600 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Dec, 2030
(8 years from now) | |
Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor; method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and a solid composition comprising amorphous and less than about 30% crystalline ivacaftor; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; method of treating cystic fibrosis; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cystic fibrosis in a patient age 12 years or older who is homozygous for the f508del mutation in the cftr gene using the tablet comprising lumacaftor as recited in claim 1, 19, or 21 of u.s. patent no. 10,076,513 and ivacaftor; Treatment of cystic fibrosis in patients 6 years and older who are homozygous for the f508del mutation in the cftr gene using the tablet according to claim 1 of u.s. patent no. 11,052,075, where the tablet further comprises ivacaftor; Method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor and ivacaftor as recited in claim 1 of us patent 9192606; Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338; method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
Dosage: GRANULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 125MG/PACKET;100MG/PACKET | GRANULE;ORAL | Prescription |
| 188MG/PACKET;150MG/PACKET | GRANULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.